Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment

Gürakar, Arzu R.; Hoeg, Jeffrey M.; Kostner, Gerhard M.; Papadopoulos, Nicholas M.; Brewer, H. Bryan

doi:10.1016/0021-9150(85)90041-3

Cited by 262 publications

(66 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of fish oil in combination with regular physical exercise lowered Lp(a) by 23% [43], as did the loss of weight [44]. Although lipidlowering agents generally do not influence Lp(a) levels [I 71, the combination of neomycin and niacin resulted in a reduction of Lp(aj [45].…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein(a) levels in relation to diabetic complications in patients with non‐insuIin‐dependent diabetes

Heesen¹,

Wolffenbuttel²,

Leurs³

et al. 1993

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract.The relationship between serum levels of lipoprotein(a) (Lp(a)) and the presence of chronic diabetic complications was studied in 194 patients with non-insulin-dependent diabetes mellitus (NIDDM; 75 males, 119 females; age 6 6 k 1 1 years; duration of diabetes, 11 (range 1-35) years). They were taking various treatments (diet alone, oral hypoglycaemic agents and/or insulin). Metabolic status and prevalence of diabetic complications were assessed by detailed history, physical examination, laboratory analysis and ECG. Average metabolic control was moderate (HbAI, 8.2f 1.7%). Median serum Lp(a) level was 183 U 1-' (range 8-2600 U I-'), which was significantly higher than in control subjects of comparable age (median 101; range 8-1747 U I-'; P

show abstract

Section: Discussionmentioning

confidence: 99%

Lipoprotein(a) levels in relation to diabetic complications in patients with non‐insuIin‐dependent diabetes

Heesen¹,

Wolffenbuttel²,

Leurs³

et al. 1993

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Lp(a) is not affected by most cholesterol-lowering drugs (9,12), however, stanazolol (13), neomycin and niacin in combination (14), nicotinic acid (15), N-acetylcysteine (16), and diethylstilbesterol ( 17) are reported to reduce serum or plasma Lp(a) levels. Stanazolol decreases both Lp(a) and HDLcholesterol levels, but does not change the apolipoprotein B level in plasma (13).…”

Section: Discussionmentioning

confidence: 99%

“…Stanazolol decreases both Lp(a) and HDLcholesterol levels, but does not change the apolipoprotein B level in plasma (13). Nicotinic acid treatments combined with and without neomycin decrease serum Lp(a) and LDLcholesterol concentrations in patients with hyperlipidemia (14,15). While N-acetylcysteine, a disulphide bond-reducing agent, reduces the serum levels of Lp(a), it was shown to increase the LDL cholesterol level in 2 patients with hyperlipidemia (16).…”

Section: Discussionmentioning

confidence: 99%

Glucocorticoid Therapy Decreases Serum Lipoprotein(a) Concentration in Rheumatic Diseases.

Aoki

Kawai

1993

Intern. Med.

View full text Add to dashboard Cite

Lipoprotein(a) has been strongly suggested to be a risk factor for atherosclerosis. However, its metabolism and/or regulation by drug treatment still remain unknown.Wetherefore studied the effects of glucocorticoid therapy on serum lipoprotein(a) in rheumatic diseases. Although the glucocorticoid treatment increased the total serum cholesterol, high-density lipoprotein cholesterol and apolipoprotein B concentrations, it reduced the serum lipoprotein(a) concentration (mean, 40%) in a dose-dependent manner in 9 patients with rheumatic diseases without nephrotic syndrome. Similar results were observed in 2 patients who did have nephrotic syndrome. It is assumed that the increase of total cholesterol and apolipoprotein B in serum levels are atherogenic, whereas the increase of high-density lipoprotein cholesterol and the decrease of lipoprotein(a) are protective for atherosclerosis. The clinical outcome of the concomitant results in lipid metabolism in the development of atherosclerosis remains to be studied. (Internal Medicine 32: 382-386, 1993)

show abstract

“…This is noteworthy because few dietary or pharmaceutical interventions appear to have any effect on lipoprotein(a) levels. In addition to oestrogen, neomycin, niacin [46], stanozolol (a) (a synthetic androgen), norethisterone (a 19-nortestosteronederived progestin) [47], and tamoxifen [48] have been shown to lower lipoprotein(a) levels. Whether lowering of lipoprotein(a) is of any benefit in lowering coronary risk is unknown.…”

Section: Hormone Replacement Therapymentioning

confidence: 99%